Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care)
- Patient enrollment on track to begin this quarter
- Interim data expected in the second half of 2022
- Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases
https://finance.yahoo.com/news/moleculin-commences-phase-1b-2-130500263.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.